탈모증 시장 규모, 점유율, 동향 분석 보고서 : 질환별, 치료법별, 성별, 판매 채널별, 지역별 및 부문별 예측(2026-2033년)

Alopecia Market Summary

The global alopecia market size was valued at USD 53.3 billion in 2025 and is projected to grow from USD 56.8 billion in 2026 to USD 100.6 billion by 2033, at a CAGR of 8.5% from 2026 to 2033. Asia Pacific dominated the market, accounting for a revenue share of 33.6% in 2025.The global alopecia market is supported by the increasing clinical burden of hair loss disorders, broader access to dermatology services, and the availability of prescription therapies for different forms of alopecia.

Androgenetic alopecia remains the most common indication, affecting a substantial proportion of adult men and women worldwide, while autoimmune conditions such as alopecia areata continue to generate demand for targeted treatment options. Clinical diagnosis has improved through the wider use of dermoscopy, scalp imaging, and standardized severity assessment, enabling earlier treatment decisions. The market is also supported by growing patient awareness of medical management rather than cosmetic approaches, particularly in developed healthcare systems. Product development activity has expanded beyond topical therapies to include oral treatments, biologics, and Janus kinase (JAK) inhibitors for immune-mediated hair loss. Regulatory approvals in major markets have strengthened physician confidence in prescribing targeted therapies, while ongoing clinical studies continue to evaluate additional therapeutic pathways for different alopecia subtypes and disease severity.

Market expansion is supported by continued investment from pharmaceutical companies, dermatology-focused biotechnology firms, and specialty healthcare providers. Companies are advancing both novel molecular targets and lifecycle management strategies for existing products, with clinical programs addressing efficacy, long-term safety, and broader patient populations. Increased collaboration between biotechnology companies and larger pharmaceutical organizations has strengthened late-stage development and global commercialization capabilities. The integration of teledermatology platforms has improved patient access to specialist consultations, follow-up care, and prescription management, particularly for chronic hair loss conditions requiring long-term monitoring. At the same time, regulatory agencies continue to evaluate additional treatment options through established approval pathways, expanding the range of evidence-based therapies available to clinicians. Although treatment affordability, variable clinical response, and limited reimbursement remain considerations in several countries, continued research activity, expanding clinical evidence, and greater recognition of alopecia as a medical condition are supporting sustained development of the global alopecia market.

Global Alopecia Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global alopecia market report based on disease type, treatment type, gender, sales channel, and region:

• Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
• Alopecia Areata
• Androgenetic Alopecia
• Traction Alopecia
• Cicatricial (Scarring) Alopecia
• Others
• Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
• Minoxidil
• Finasteride & Dutasteride
• Corticosteroids
• JAK Inhibitors
• Other Pharmaceuticals
• Platelet-Rich Plasma (PRP)
• Low-Level Laser Therapy (LLLT) Devices
• Hair Transplant Procedures
• Gender Outlook (Revenue, USD Million, 2021 - 2033)
• Male
• Female
• Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Specialty Clinics / Direct Dispensing
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease Type
  • 1.2.2. Treatment Type
  • 1.2.3. Gender
  • 1.2.4. Sales Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Alopecia Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Alopecia Market: Disease Type Business Analysis

• 4.1. Disease Type Market Share, 2025 & 2033
• 4.2. Disease Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
• 4.4. Alopecia Areata
  • 4.4.1. Alopecia Areata Market, 2021 - 2033 (USD Million)
• 4.5. Androgenetic Alopecia
  • 4.5.1. Androgenetic Alopecia Market, 2021 - 2033 (USD Million)
• 4.6. Traction Alopecia
  • 4.6.1. Traction Alopecia Market, 2021 - 2033 (USD Million)
• 4.7. Cicatricial (Scarring) Alopecia
  • 4.7.1. Cicatricial (Scarring) Alopecia Market, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Alopecia Market: Treatment Type Business Analysis

• 5.1. Treatment Type Market Share, 2025 & 2033
• 5.2. Treatment Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
• 5.4. Minoxidil
  • 5.4.1. Minoxidil Market, 2021 - 2033 (USD Million)
• 5.5. Finasteride & Dutasteride
  • 5.5.1. Finasteride & Dutasteride Market, 2021 - 2033 (USD Million)
• 5.6. Corticosteroids
  • 5.6.1. Corticosteroids Market, 2021 - 2033 (USD Million)
• 5.7. JAK Inhibitors
  • 5.7.1. JAK Inhibitors Market, 2021 - 2033 (USD Million)
• 5.8. Other Pharmaceuticals
  • 5.8.1. Other Pharmaceuticals, 2021 - 2033 (USD Million)
• 5.9. Platelet-Rich Plasma (PRP)
  • 5.9.1. Platelet-Rich Plasma (PRP) Market, 2021 - 2033 (USD Million)
• 5.10. Low-Level Laser Therapy (LLLT) Devices
  • 5.10.1. Low-Level Laser Therapy (LLLT) Devices Market, 2021 - 2033 (USD Million)
• 5.11. Hair Transplant Procedures
  • 5.11.1. Hair Transplant Procedures Market, 2021 - 2033 (USD Million)

Chapter 6. Alopecia Market: Gender Business Analysis

• 6.1. Gender Market Share, 2025 & 2033
• 6.2. Gender Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Gender, 2021 to 2033 (USD Million)
• 6.4. Male
  • 6.4.1. Male Market, 2021 - 2033 (USD Million)
• 6.5. Female
  • 6.5.1. Female Market, 2021 - 2033 (USD Million)

Chapter 7. Alopecia Market: Sales Channel Business Analysis

• 7.1. Sales Channel Market Share, 2025 & 2033
• 7.2. Sales Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
• 7.4. Retail Pharmacies
  • 7.4.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
• 7.5. Hospital Pharmacies
  • 7.5.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)
• 7.7. Specialty Clinics / Direct Dispensing
  • 7.7.1. Specialty Clinics / Direct Dispensing Market, 2021 - 2033 (USD Million)

Chapter 8. Alopecia Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America Alopecia Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. Canada Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. UK Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Brazil Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. Argentina Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Pfizer Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Eli Lilly and Company
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Organon & Co.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Johnson & Johnson
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Viatris Inc.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. EmCyte Corporation
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Regen Lab SA
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Terumo Corporation
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Zimmer Biomet Holdings, Inc.
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Arthrex, Inc
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. Bosley Inc.
    • 9.5.11.1. Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Strategic Initiatives
  • 9.5.12. DHI Global Medical Group
    • 9.5.12.1. Overview
    • 9.5.12.2. Financial Performance
    • 9.5.12.3. Product Benchmarking
    • 9.5.12.4. Strategic Initiatives
  • 9.5.13. Asmed Hair Transplant Center
    • 9.5.13.1. Overview
    • 9.5.13.2. Financial Performance
    • 9.5.13.3. Product Benchmarking
    • 9.5.13.4. Strategic Initiatives
  • 9.5.14. Bernstein Medical
    • 9.5.14.1. Overview
    • 9.5.14.2. Financial Performance
    • 9.5.14.3. Product Benchmarking
    • 9.5.14.4. Strategic Initiatives
  • 9.5.15. Hairline International Hair and Skin Clinic
    • 9.5.15.1. Overview
    • 9.5.15.2. Financial Performance
    • 9.5.15.3. Product Benchmarking
    • 9.5.15.4. Strategic Initiatives